All In Biotech

Investigational drug · Phase 2

OpRegen

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Age-Related Macular Degeneration, Geographic Atrophy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "OpRegen"

First trial start

2015

Apr 1, 2015

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "OpRegen", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Age-Related Macular Degeneration
  • Geographic Atrophy

Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "OpRegen" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Age-Related Macular Degeneration

  • TiespectusEYE201, MK-8748Phase 35 trials

    EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization

  • ABBV-6628Phase 21 trial

    AbbVie · Geographic Atrophy, Age-Related Macular Degeneration

  • KH631Phase 21 trial

    Chengdu Origen Biotechnology Co., Ltd. · Age-Related Macular Degeneration

  • KH658Phase 21 trial

    Chengdu Origen Biotechnology Co., Ltd. · Age-related Macular Degeneration

  • SOM-401Phase 21 trial

    Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration

  • VOY-101Phase 21 trial

    Perceive Biotherapeutics, Inc. · Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.